Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
RHTC will address a long-standing healthcare access issue for all the local population
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
The total investment is in the region of Rs 200 crore
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Subscribe To Our Newsletter & Stay Updated
